Adaptive Biotechnologies (NASDAQ:ADPT) Insider Harlan Robins Sells 492,400 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 492,400 shares of the stock in a transaction that occurred on Tuesday, July 21st. The stock was sold at an average price of $21.89, for a total transaction of $10,778,636.00. Following the completion of the sale, the insider directly owned 812,058 shares of the company’s stock, valued at $17,775,949.62. This trade represents a 37.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies Stock Performance

Shares of ADPT stock traded up $0.14 during trading on Tuesday, hitting $22.68. 428,289 shares of the company were exchanged, compared to its average volume of 2,299,114. The firm has a market capitalization of $3.63 billion, a price-to-earnings ratio of -68.63 and a beta of 2.07. The business’s 50-day simple moving average is $18.69 and its 200 day simple moving average is $16.47. Adaptive Biotechnologies Corporation has a twelve month low of $9.96 and a twelve month high of $23.15.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The firm had revenue of $70.87 million for the quarter, compared to analyst estimates of $61.03 million. During the same quarter in the prior year, the business earned ($0.20) EPS. The company’s revenue for the quarter was up 35.1% compared to the same quarter last year. On average, equities analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Wasatch Advisors LP acquired a new stake in Adaptive Biotechnologies in the 2nd quarter worth approximately $12,361,000. Handelsbanken Fonder AB acquired a new position in Adaptive Biotechnologies during the second quarter valued at approximately $1,416,000. Assenagon Asset Management S.A. acquired a new position in Adaptive Biotechnologies during the second quarter valued at approximately $512,000. Perceptive Advisors LLC bought a new position in shares of Adaptive Biotechnologies in the first quarter valued at approximately $2,117,000. Finally, Bank of America Corp DE raised its position in shares of Adaptive Biotechnologies by 52.3% in the first quarter. Bank of America Corp DE now owns 1,227,917 shares of the company’s stock valued at $17,043,000 after purchasing an additional 421,645 shares during the period. 99.17% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ADPT. JPMorgan Chase & Co. cut their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Morgan Stanley boosted their target price on shares of Adaptive Biotechnologies from $18.00 to $20.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th. TD Cowen restated a “buy” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, July 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Friday, July 17th. Finally, Guggenheim raised their price target on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a report on Monday, June 29th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $20.83.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.